AR116937A1 - Anticuerpo monoclonal que se une específicamente al antígeno cd20 - Google Patents

Anticuerpo monoclonal que se une específicamente al antígeno cd20

Info

Publication number
AR116937A1
AR116937A1 ARP190103167A ARP190103167A AR116937A1 AR 116937 A1 AR116937 A1 AR 116937A1 AR P190103167 A ARP190103167 A AR P190103167A AR P190103167 A ARP190103167 A AR P190103167A AR 116937 A1 AR116937 A1 AR 116937A1
Authority
AR
Argentina
Prior art keywords
antigen
antibody
binding fragment
seq
nucleic acid
Prior art date
Application number
ARP190103167A
Other languages
English (en)
Inventor
Sergei Vasilyevich Diduk
Alexey Konstantinovich Misorin
Valery Vladimirovich Solovyev
Nina Grachyaevna Kharatian
Mariia Aleksandrovna Shchemeleva
Anna Alexandrovna Trudovishnikova
Arina Vitalevna Anikina
Natalia Eugenievna Pestova
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Roman Alekseevich Ivanov
Svetlana Vladimirovna Koskova
Iana Andreevna Smirnova
Aleksei Aleksandrovich Aleksandrov
Elena Andreevna Krendeleva
Veronika Sergeevna Usatova
Iakov Iurevich Ustiugov
Anna Vladimirovna Eroshova
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR116937A1 publication Critical patent/AR116937A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente se refiere a la biotecnología y proporciona un anticuerpo monoclonal que se une específicamente al antígeno CD20. La presente también se refiere a ADN que codifica dicho anticuerpo, los correspondientes vectores de expresión y métodos para su producción, al igual que métodos de tratamiento para emplear dicho anticuerpo. Reivindicación 1: Un anticuerpo monoclonal o fragmento de unión al antígeno de este que se une específicamente a CD20 que comprende: a) un dominio variable de la cadena pesada que comprende una secuencia de aminoácidos que se muestra en la SEQ ID Nº 2 o SEQ ID Nº 6; b) un dominio variable de la cadena ligera que comprende una secuencia de aminoácidos que se muestra en la SEQ ID Nº 4 o SEQ ID Nº 8. Reivindicación 10: Un ácido nucleico que codifica un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9. Reivindicación 12: Un vector de expresión que comprende un ácido nucleico según cualquiera de las reivindicaciones 10 - 11. Reivindicación 13: Un método para la producción de una célula hospedante para producir un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9 que comprende la transformación de una célula con un vector según la reivindicación 12. Reivindicación 14: Una célula hospedante para producir un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9, que comprende un ácido nucleico según cualquiera de las reivindicaciones 10 - 11. Reivindicación 15: Un método para la producción de un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9, que comprende cultivar una célula hospedante según la reivindicación 14 en un medio de cultivo en condiciones suficientes para producir dicho anticuerpo o fragmento de unión al antígeno de este, si es necesario, seguido del aislamiento y la purificación del anticuerpo producido o de un fragmento de unión al antígeno de este. Reivindicación 16: Una composición farmacéutica para la profilaxis o el tratamiento de una enfermedad o un trastorno mediado por CD20, que comprende un anticuerpo o fragmento de unión al antígeno de este según cualquiera de las reivindicaciones 1 - 9 en combinación con uno o más excipientes farmacéuticamente aceptables.
ARP190103167A 2018-10-31 2019-10-31 Anticuerpo monoclonal que se une específicamente al antígeno cd20 AR116937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018138510A RU2724469C2 (ru) 2018-10-31 2018-10-31 Моноклональное антитело, которое специфически связывается с cd20

Publications (1)

Publication Number Publication Date
AR116937A1 true AR116937A1 (es) 2021-06-30

Family

ID=70462324

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103167A AR116937A1 (es) 2018-10-31 2019-10-31 Anticuerpo monoclonal que se une específicamente al antígeno cd20

Country Status (25)

Country Link
US (1) US20220089761A1 (es)
EP (1) EP3875486A4 (es)
JP (1) JP2022506430A (es)
KR (1) KR20210084604A (es)
CN (1) CN113272329A (es)
AR (1) AR116937A1 (es)
AU (1) AU2019373999A1 (es)
BR (1) BR112021008326A2 (es)
CA (1) CA3117486A1 (es)
CL (1) CL2021001104A1 (es)
CO (1) CO2021005178A2 (es)
EA (1) EA202191173A1 (es)
EC (1) ECSP21028958A (es)
IL (1) IL282742A (es)
JO (1) JOP20210100A1 (es)
MA (1) MA53186B2 (es)
MX (1) MX2021005033A (es)
PE (1) PE20211731A1 (es)
PH (1) PH12021550991A1 (es)
RU (1) RU2724469C2 (es)
SG (1) SG11202104248UA (es)
TW (1) TW202031682A (es)
UY (1) UY38432A (es)
WO (1) WO2020091634A1 (es)
ZA (1) ZA202102874B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024025440A1 (en) * 2022-07-26 2024-02-01 Joint Stock Company "Biocad" Pharmaceutical composition of anti-cd20 antibody and use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
DE69006018T3 (de) 1989-03-21 2004-01-15 Immune Response Corp Inc Impfung und methoden gegen krankheiten, die von pathologischen reaktionen der spezifischen t-zellen abstammen.
DK0552142T3 (da) 1989-07-19 1998-09-07 Connetics Corp T-cellereceptorpeptider og terapeutika til autoimmune og maligne sygdomme
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
AU2011226858B2 (en) * 2002-12-16 2015-01-22 Genentech, Inc. Immunoglobulin variants and uses thereof
ES2322267T3 (es) 2003-04-09 2009-06-18 Genentech, Inc. Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
RU2489166C2 (ru) 2006-04-09 2013-08-10 Джинентех, Инк. Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
TW201129383A (en) * 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
CN102190728B (zh) * 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体

Also Published As

Publication number Publication date
SG11202104248UA (en) 2021-05-28
MA53186A1 (fr) 2022-02-28
US20220089761A1 (en) 2022-03-24
RU2018138510A (ru) 2020-04-30
ECSP21028958A (es) 2021-05-31
MA53186B2 (fr) 2023-05-31
UY38432A (es) 2020-05-29
JOP20210100A1 (ar) 2023-01-30
CA3117486A1 (en) 2020-05-07
MX2021005033A (es) 2021-06-15
ZA202102874B (en) 2022-06-29
CO2021005178A2 (es) 2021-04-30
BR112021008326A2 (pt) 2021-08-31
KR20210084604A (ko) 2021-07-07
CN113272329A (zh) 2021-08-17
EP3875486A1 (en) 2021-09-08
EA202191173A1 (ru) 2021-07-28
AU2019373999A1 (en) 2021-05-27
TW202031682A (zh) 2020-09-01
EP3875486A4 (en) 2022-08-03
PH12021550991A1 (en) 2021-10-04
JP2022506430A (ja) 2022-01-17
CL2021001104A1 (es) 2021-12-03
RU2724469C2 (ru) 2020-06-23
IL282742A (en) 2021-06-30
WO2020091634A1 (ru) 2020-05-07
PE20211731A1 (es) 2021-09-06
RU2018138510A3 (es) 2020-04-30

Similar Documents

Publication Publication Date Title
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
ECSP18084153A (es) Anticuerpos anti-BASIGIN humanizados y uso de los mismos
EA201992206A1 (ru) Моноклональное антитело к pd-l1
PE20230160A1 (es) Anticuerpos especificos para cd47, pd-l1 y sus usos
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
PH12021550244A1 (en) Anti-btla antibody
AR109857A1 (es) Anticuerpos anti-chikv y usos de éstos
EA201991845A1 (ru) Фармацевтические комбинации, содержащие антитело к ly75
AR110755A1 (es) Anticuerpos dirigidos a hueso
AR116937A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
AR124084A1 (es) ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO
PE20230384A1 (es) Anticuerpos cd163 o proteinas de union
AR083971A1 (es) Anticuerpos antiproliferacion humanizados homogeneos
EA202090864A1 (ru) Моноклональное антитело к il-5r
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso
AR122286A1 (es) Anticuerpos potenciadores del factor h y usos de estos
AR124906A1 (es) Materiales y métodos para dirigirse a las células t reguladoras para potenciar la vigilancia inmunitaria
AR100311A1 (es) Anticuerpos multiespecíficos
UY39687A (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
AR121867A1 (es) Anticuerpos monoclonales anti-sars-cov-2
AR127445A1 (es) Anticuerpos de unión a claudina 18.2 y fragmentos de estos
AR126185A1 (es) Anticuerpo biespecífico aislado que se une específicamente a cd47 y pd-l1